Christopher Richard Anzalone Sells 50,800 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 50,800 shares of the stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total value of $583,692.00. Following the sale, the chief executive officer now directly owns 3,921,255 shares of the company’s stock, valued at approximately $45,055,219.95. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Wednesday, April 9th, Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $10.07, for a total transaction of $406,042.54.
• On Thursday, March 13th, Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75.
• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $11.79 on Friday. The stock has a market cap of $1.62 billion, a P/E ratio of -2.28 and a beta of 0.99. The company has a fifty day moving average price of $16.07 and a two-hundred day moving average price of $18.86. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $38,000. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $49,000. Van ECK Associates Corp grew its stake in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV raised its holdings in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares during the period. Finally, Mackenzie Financial Corp acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $137,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ARWR. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. B. Riley reaffirmed a “buy” rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.